News Laquinimod failure is bad news for Teva's MS hopes Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a late stage trial.
News FDA approves first ALS treatment for two decades FDA asked Mitsubishi to file Radicava following approval in Japan.
News Biotech IPO market heats up as BioHaven's debut impresses BioHaven raises $168 million with biggest biotech IPO seen this year.
News Biogen shares up after strong launch for rare disease drug US insurers are covering the treatment, despite high price.
News FDA approves Teva's Huntington's Disease drug First treatment approved for Huntington's Disease in almost a decade.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
